PharmTech Drug Digest 11.20
News|Articles|June 7, 2016

Thermo Fisher Scientific Releases New Biopharmaceutical Characterization Technology

The company showcased new technologies at ASMS for biopharmaceutical characterization.

Thermo Fisher Scientific released new technologies for biopharmaceutical characterization at the American Society for Mass Spectrometry Conference (ASMS) in Texas, the company said in a press announcement. One of the featured products included Thermo Scientific’s Q Exactive BioPharma MS/MS Hybrid Quadropole-Orbitrap mass spectrometer. The spectrometer uses high-resolution, accurate-mass (HRAM) capabilities of the Orbitrap mass analyzer to enable key workflows for protein characterization in a single instrument. Combined with recommended sample preparation and analysis methods using Thermo Scientific reagents, columns, ultra high-pressure liquid chromatography (UHPLC) and data processing technologies, the Q Exactive BioPharma system provides a comprehensive solution for biopharmaceutical characterization. The company also showcased its new workflow driven software and cloud solutions to allow users to analyze insights in several applications, including proteomics, metabolomics, food safety, and biopharmaceutical characterization.

Source: Thermo Fisher Scientific


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.